Target intelligence / Profile preview

B-cell lymphoma 2 and B-cell lymphoma-extra large (Bcl-2 and Bcl-xL)

Target: Bcl-2 and Bcl-xL
Molecular classification: Apoptosis regulator, Mitochondrial protein, Anti-apoptotic protein (Bcl-2 family), Transmembrane protein

Overview

B-cell lymphoma 2 (Bcl-2) and B-cell lymphoma-extra large (Bcl-xL) are closely related, evolutionarily conserved proteins in the Bcl-2 family that function as key negative regulators of apoptosis. Located primarily at the mitochondrial outer membrane, they inhibit programmed cell death by blocking the release of pro-apoptotic mitochondrial contents (such as cytochrome c), chiefly through interactions with pro-apoptotic family members (e.g., Bax, Bak) and the voltage-dependent anion channel (VDAC). Dysregulation and overexpression of these proteins are strongly linked to tumorigenesis by promoting cancer cell survival and therapy resistance. Bcl-2/Bcl-xL have become prominent therapeutic targets in oncology, with several drugs developed to antagonize their function, restore apoptosis, and improve cancer treatment outcomes.

Other names: BCL2 (for B-cell lymphoma 2)BCL2L1 or BCL-X(L) (for B-cell lymphoma-extra large)Bcl-2-like 1BCL-XL

Mechanism of action

Direct binding and inhibition of Bcl-2/Bcl-xL to restore apoptosis in cancer cells Mimicking BH3-only proteins to disrupt Bcl-2/Bcl-xL interaction with pro-apoptotic partners (resulting in cytochrome c release and caspase activation)

Biological functions

Inhibition of apoptosisRegulation of mitochondrial membrane permeabilizationRegulation of cellular calcium signalingModulation of autophagy

Disease associations

Cancer (especially hematological malignancies and solid tumors)Possibly neurodegenerative disease (due to apoptosis pathway involvement)Other diseases involving dysregulated apoptosis

Safety considerations

Thrombocytopenia (especially with Bcl-xL inhibition, as Bcl-xL is critical for platelet survival)Tumor lysis syndrome (rapid restoration of apoptosis in some cancers)Resistance mechanisms due to upregulation of alternative anti-apoptotic proteins

Interacting drugs

Venetoclax (Bcl-2 selective inhibitor)

4 more in the full profile.

Biomarkers

Expression levels of Bcl-2 and/or Bcl-xL in tumor tissue (for drug sensitivity prediction or patient selection)Mitochondrial membrane potential changes (as downstream efficacy markers)Caspase activation status (in efficacy monitoring)

Beyond the preview

Go deeper on B-cell lymphoma 2 and B-cell lymphoma-extra large (Bcl-2 and Bcl-xL).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

Drug candidates
Developers
Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

Trial design
Status
Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

Programs
Modalities
Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

Publications
Sources
Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

Patents
Assignees
Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

Biology
Development news
Analysis

Bring the full picture into focus.

See how Gosset can support your research on B-cell lymphoma 2 and B-cell lymphoma-extra large (Bcl-2 and Bcl-xL).

Explore the full profile